Loading this company
Loading this company
Too wide to call. Our lenses land between CHF 49.06 and CHF 184.93, which is too broad to say where today’s price sits in it.
CHF 123.92CHF down −CHF 0.78 (−0.63%)
Quoted · Prices are delayed.
Nothing we can cite explains today’s move for this company.
Our range from 4 models, on today’s numbers
CHF 49.06–CHF 184.93
What the price needs: revenue growth of 0.6%/yr for 5 years (our model assumes 2.4%).
Led by discounted cash flow (DCF) · Dividend income business
Delayed price used by the model CHF 124.70Prices are delayed.
Our forward range over 12 months is part of Pro. See plans
Analysts’ mean target
CHF 123.81 across 22 analysts
The high and low of the analyst range is part of Pro. See plans
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It operates in the Drug Manufacturers - General industry (Healthcare sector), headquartered in Switzerland. The company employs roughly 75,267 people.
Prices are delayed. The feed does not say when these figures were taken.
No filings or corporate activity on file in the recent window.
No recent headlines we can cite for this company.
No insider filings for this company in the recent window.
Not investment advice. TickerWorth Score is a model output.
The score, the fair value and the reverse DCF are free on every company. Pro lets you change growth, margin and the discount rate yourself, see every valuation lens and its working, and download the model. Start a 7-day free trial — a card is required and you can cancel any time before it ends. $99 a year, or $14.99 monthly.